Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Phleum Pratense in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Grass Pollen

NCT01682070 is registered in ClinicalTrials.gov with HAL Allergy as lead sponsor.

NCT NCT01682070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01682070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Phleum Pratense in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Grass Pollen
Lead sponsor
HAL Allergy
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
May 31, 2013
Enrollment
266 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis, allergic rhinoconjunctivitis